文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

间质性肺疾病中的肺动脉高压:系统评价与Meta分析

Pulmonary Hypertension in Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
PubMed 文献 · Chest · 2024-05-29
一句话结论间质性肺疾病患者中肺动脉高压患病率约36%(右心导管)和34%(经胸超声心动图),与症状负担增加和预后更差相关。

该系统评价与Meta分析纳入302项原始研究,评估间质性肺疾病(ILD)患者中肺动脉高压(PH)的诊断评估、流行病学特征、相关因素、预后意义及干预试验结局指标。常用诊断方法为右心导管(56%)和经胸超声心动图(50%)。右心导管定义的PH合并患病率为36%(95%CI 30%-42%),经胸超声心动图定义的为34%(95%CI 29%-38%)。PH的存在与症状负担增加和预后更差相关;干预试验结局指标集中于肺血管血流动力学变化和6分钟步行距离。作者认为需要标准化定义及基于相关风险因素的前瞻性风险分层评估。

要点

  • ILD患者中PH的合并患病率:右心导管36%(95%CI 30%-42%),经胸超声心动图34%(95%CI 29%-38%)。
  • 常用诊断方法:右心导管(56%)和经胸超声心动图(50%),各研究诊断标准不一。
  • 至少60%的研究报告PH与DLCO降低、氧合状态更差、运动能力下降、肺动脉/主动脉比值及肺动脉直径增加、血清BNP升高相关。
  • PH存在与症状负担增加和预后更差相关。
  • PH干预试验结局指标集中于肺血管血流动力学变化和6分钟步行距离。

适用人群与场景

  • 任何病因的间质性肺疾病(ILD)患者,来自评估PH的原始研究。

诊断标准与关键阈值

  • PH定义基于各研究者的标准,系统评价未统一诊断标准。

研究设计与关键结果

  • 纳入302项研究,诊断评估方法不一。
  • 常用诊断试验:右心导管56%,经胸超声心动图50%。
  • ILD总体人群中PH合并患病率:右心导管36%(95%CI 30%-42%),经胸超声心动图34%(95%CI 29%-38%)。
  • 至少60%的研究报告PH与DLCO降低、氧合状态更差、运动能力下降、肺动脉/主动脉比值及肺动脉直径增加、血清BNP升高相关。
  • PH存在与症状负担增加和预后更差相关。
  • PH干预试验结局指标聚焦于肺血管血流动力学变化和6分钟步行距离。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入302项原始研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为需要标准化定义及基于已识别风险因素的前瞻性风险分层评估。
  • 作者认为研究结果为未来ILD中PH干预试验的替代终点验证提供了证据基础。

指南或共识出处

  • Chest发表的系统评价与Meta分析,PROSPERO注册号CRD42021255394。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Pulmonary hypertension (PH) is a key complication in interstitial lung disease (ILD), with recent therapeutic advances.

RESEARCH QUESTION: What are the diagnostic evaluation, epidemiologic features, associated factors, prognostic significance, and outcome measures in interventional trials for PH in patients with ILD in the current literature?

STUDY DESIGN AND METHODS: The Ovid MEDLINE, Embase, and CENTRAL databases were searched for original research evaluating PH in participants with ILD of any cause. The definition of PH was based on the investigators' criteria.

RESULTS: Three hundred two studies were included, with varying diagnostic evaluations used to define PH. Commonly used diagnostic tests were right heart catheterization (56%) and transthoracic echocardiography (50%). The pooled prevalence for PH in general populations with ILD was 36% (95% CI, 30%-42%) using right heart catheterization and 34% (95% CI, 29%-38%) using transthoracic echocardiography. Lower diffusion capacity of the lungs for carbon monoxide, worse oxygenation status, reduced exercise capacity, increased pulmonary artery to aorta ratio and pulmonary artery diameter, and elevated serum brain natriuretic peptide consistently were associated with the presence of PH in at least 60% of reported studies. The presence of PH was associated with increased symptom burden and worse prognosis. Outcome measures in interventional trials of PH in ILD focused on changes in pulmonary vascular hemodynamics and 6-min walk distance.

INTERPRETATION: PH is a common complication in ILD with significant health impacts. A standardized definition with prospective evaluation of risk-stratified assessments for PH using identified associated risk factors is warranted. Our findings provide an evidence base for validation as surrogate end points in future PH interventional trials in ILD.

TRIAL REGISTRY: International Prospective Register of Systematic Reviews; No.: CRD42021255394; URL: https://www.crd.york.ac.uk/prospero/.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Ang HL, Schulte M, Chan RK, et al. Pulmonary Hypertension in Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Chest. 2024. PMID: 38821182. doi:10.1016/j.chest.2024.04.025

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。